Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surrogates for fracture endpoints in clinical trials.

× No keyword cloud information.

9 in total

Review 1. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.

Authors: Paul D Miller
Journal: Curr Osteoporos Rep Date: 2005-09 Impact factor: 5.096

2. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.

Authors: M Vis; I E M Bultink; B A C Dijkmans; W F Lems
Journal: Osteoporos Int Date: 2005-05-10 Impact factor: 4.507

3. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

Authors: David M Reid; David Hosking; David Kendler; Maria L Brandi; John D Wark; Georges Weryha; João F Marques-Neto; Keavy A Gaines; Nadia Verbruggen; Mary E Melton
Journal: Clin Drug Investig Date: 2006 Impact factor: 2.859

4. Preservation of bone structure and function by Lithothamnion sp. derived minerals.

Authors: Muhammad Nadeem Aslam; Ingrid Bergin; Karl Jepsen; Jaclynn M Kreider; Kristin H Graf; Madhav Naik; Steven A Goldstein; James Varani
Journal: Biol Trace Elem Res Date: 2013-10-06 Impact factor: 3.738

Review 5. Inadequate responders to osteoporosis treatment: proposal for an operational definition.

Authors: A Díez-Pérez; J González-Macías
Journal: Osteoporos Int Date: 2008-06-11 Impact factor: 4.507

Review 6. True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo.

Authors: Matthew R Allen; Erin Mb McNerny; Jason M Organ; Joseph M Wallace
Journal: J Bone Miner Res Date: 2015-08-06 Impact factor: 6.741

Review 7. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Authors: Jean-Yves Reginster; Dieter Felsenberg; Cyrus Cooper; Jacob A Stakkestad; Paul D Miller; David L Kendler; Silvano Adami; Michael R McClung; Michael A Bolognese; Roberto Civitelli; Etienne Dumont; Bernard Bonvoisin; Robert R Recker; Pierre D Delmas
Journal: Osteoporos Int Date: 2005-06-14 Impact factor: 4.507

8. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials.

Authors: Shenghan Lou; Houchen Lv; Zhirui Li; Licheng Zhang; Peifu Tang
Journal: BMJ Open Date: 2018-03-01 Impact factor: 2.692

9. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.

Authors: Danielle A Eekman; Marijn Vis; Irene E M Bultink; Harm J G M Derikx; Ben A C Dijkmans; Willem F Lems
Journal: BMC Musculoskelet Disord Date: 2009-07-15 Impact factor: 2.362

9 in total